Plain-English translation of NCT07209475 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing , a cellular healing patch made from amnion tissue, to see if it helps chronic diabetic foot ulcers heal faster. Researchers will compare people who receive the patch along with standard wound care to people who receive standard care alone. The goal is to find out whether this treatment can help stubborn foot wounds close more effectively.
Diabetic foot ulcers are difficult to heal and can lead to serious complications like infection or amputation. This medication may help speed healing by providing biological support to the wound, but researchers need to test whether it truly works better than current standard treatments.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will first go through a 2-week screening period where your ulcer will be carefully monitored and cleaned. Then you will be randomly assigned to either receive standard wound care alone, or standard wound care plus the Amnio-Maxx® healing patch applied to your ulcer. You will need to attend multiple clinic visits for wound care, measurements, and check-ups, and you must consistently wear an offloading device to protect your foot throughout the study. The study will track how well your ulcer heals over time.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
United States